Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
The primary aim of the study is to identify genomic markers (circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society